Cognizant Expands AI-Enabled DevOps Capabilities for Gilead Sciences
- Cognizant secures five-year extension to manage Gilead's digital infrastructure
- Deal leans heavily on 'AI-enabled' DevOps to streamline drug development tech
- Gilead doubles down on outsourcing to keep the medicine-making machine humming
- Corporate buzzword bingo: 'Digital transformation' meets biopharma bottom lines
Brief Summary
Cognizant and Gilead Sciences have locked arms for another five years, turning over the keys to Gilead's technology operations to the IT consulting giant. The deal is framed around 'AI-enabled' DevOps, promising to speed up the digital heavy lifting behind the scenes of one of the world's largest pharmaceutical outfits.
Why This Matters
When massive biopharma companies outsource their digital backbone, they are betting that outside consultants can run their internal operations more efficiently than their own staff. For you, this means the drugs you rely on are increasingly being developed and managed through complex, automated systems maintained by third-party contractors. If these AI-driven systems hit a snag or a security breach, the ripple effects could hit the pharmaceutical supply chain where it hurts, potentially slowing down access to critical life-saving medications.